FDA approve dupilumab for atopic dermatitis in children aged 6-11 years

Approval of this interleukin-4 inhibitor was based on phase III trial which found an 84% improvement in EASI score from baseline for dupilumab every 4 weeks, 80% for dulipumab every 2 weeks vs 49% and 48% controls. In UK, currently only approved for use in children age ≥12 years.


Biospace Inc.